

3. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. *Cardiovasc Res.* 2002;53:313–325.
4. Jeanpierre E, Le Tourneau T, Six I, et al. Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: a potential role of tissue factor. *Circulation.* 2003;108:1740–1745.
5. Kuge Y, Kume N, Ishino S, et al. Prominent lectin-like oxidized low density lipoprotein (LDL) receptor-1 (LOX-1) expression in atherosclerotic lesions is associated with tissue factor expression and apoptosis in hypercholesterolemic rabbits. *Biol Pharm Bull.* 2008;31:1475–1482.
6. Shiomi M, Ito T, Yamada S, Kawashima S, Fan J. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). *Arterioscler Thromb Vasc Biol.* 2003;23:1239–1244.
7. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. *J Nucl Med.* 1990;31:2022–2028.
8. Ono M, Arano Y, Mukai T, et al. Plasma protein binding of ^{99m}Tc-labeled hydrazino nicotinamide derivatized polypeptides and peptides. *Nucl Med Biol.* 2001;28:155–164.
9. Larsen SK, Solomon HF, Caldwell G, Abrams MJ. [^{99m}Tc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinamide protein conjugates. *Bioconjug Chem.* 1995;6:635–638.
10. Ishii K, Kita T, Kume N, Nagano Y, Kawai C. Uptake of acetylated LDL by peritoneal macrophages obtained from normal and Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia. *Biochim Biophys Acta.* 1988;962:387–389.
11. Ogawa M, Ishino S, Mukai T, et al. ¹⁸F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. *J Nucl Med.* 2004;45:1245–1250.
12. Sary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation.* 1994;89:2462–2478.
13. Sary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation.* 1995;92:1355–1374.
14. Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. *Arterioscler Thromb Vasc Biol.* 2003;23:1398–1404.
15. Ishino S, Kuge Y, Takai N, et al. ^{99m}Tc-Annexin A5 for noninvasive characterization of atherosclerotic lesions: imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. *Eur J Nucl Med Mol Imaging.* 2007;34:889–899.
16. Shiomi M, Ito T, Hirouchi Y, Enomoto M. Stability of atheromatous plaque affected by lesional composition: study of WHHL rabbits treated with statins. *Ann N Y Acad Sci.* 2001;947:419–423.
17. Ishino S, Mukai T, Kuge Y, et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with ^{99m}Tc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. *J Nucl Med.* 2008;49:1677–1685.
18. Shiomi M, Ito T, Hirouchi Y, Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. *Atherosclerosis.* 2001;157:75–84.
19. Huhlov A, Chester KA. Engineered single chain antibody fragments for radioimmunotherapy. *Q J Nucl Med Mol Imaging.* 2004;48:279–288.
20. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radio-nuclides for imaging and therapy of cancer using pretargeting methods. *Clin Cancer Res.* 2005;11:7109s–7121s.
21. Sano K, Temma T, Kuge Y, et al. Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method. *Biol Pharm Bull.* 2010;33:1589–1595.
22. Temma T, Iida H, Hayashi T, et al. Quantification of regional myocardial oxygen metabolism in normal pigs using positron emission tomography with injectable ¹⁵O-O₂. *Eur J Nucl Med Mol Imaging.* 2010;37:377–385.
23. Yamamoto Y, de Silva R, Rhodes CG, et al. Noninvasive quantification of regional myocardial metabolic rate of oxygen by ¹⁵O₂ inhalation and positron emission tomography: experimental validation. *Circulation.* 1996;94:808–816.
24. Iida H, Rhodes CG, Araujo LI, et al. Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of ¹⁵O₂ inhalation and positron emission tomography: theory, error analysis, and application in humans. *Circulation.* 1996;94:792–807.
25. Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M. PET kinetic analysis: compartmental model. *Ann Nucl Med.* 2006;20:583–588.
26. Ikoma Y, Watabe H, Shidahara M, Naganawa M, Kimura Y. PET kinetic analysis: error consideration of quantitative analysis in dynamic studies. *Ann Nucl Med.* 2008;22:1–11.
27. Rogers BE, Anderson CJ, Connett JM, et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: bio-distribution and metabolism. *Bioconjug Chem.* 1996;7:511–522.
28. Sugimoto K, Nishimoto N, Kishimoto T, Yoshizaki K, Nishimura T. Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleu-kin-6 receptor antibody. *Ann Nucl Med.* 2005;19:261–266.
29. D'Alessandria C, Malviya G, Viscido A, et al. Use of a ^{99m}Tc labeled anti-TNF α monoclonal antibody in Crohn's disease: in vitro and in vivo studies. *Q J Nucl Med Mol Imaging.* 2007;51:334–342.
30. Akizawa H, Arano Y. Altering pharmacokinetics of radiolabeled antibodies by the interposition of metabolizable linkages: metabolizable linkers and pharmacokinetics of monoclonal antibodies. *Q J Nucl Med.* 2002;46:206–223.
31. Campean V, Neureiter D, Varga I, et al. Atherosclerosis and vascular calcification in chronic renal failure. *Kidney Blood Press Res.* 2005;28:280–289.
32. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. *Am J Pathol.* 1989;134:1087–1097.
33. Prezelj A, Anderlueh PS, Peternel L, Urleb U. Recent advances in serine protease inhibitors as anticoagulant agents. *Curr Pharm Des.* 2007;13:287–312.
34. Davies JR, Rudd JH, Weissberg PL, Narula J. Radionuclide imaging for the detection of inflammation in vulnerable plaques. *J Am Coll Cardiol.* 2006;47(8, suppl):C57–C68.
35. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. *J Am Coll Cardiol.* 2006;47:1328–1338.
36. Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2009;29:1009–1016.
37. Zhao Y, Kuge Y, Zhao S, et al. Comparison of ^{99m}Tc-annexin A5 with ¹⁸F-FDG for the detection of atherosclerosis in ApoE^{-/-} mice. *Eur J Nucl Med Mol Imaging.* 2007;34:1747–1755.

Erratum

In the article “¹⁸F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma,” by Cerci et al. (*J Nucl Med.* 2010;51:1337–1343), Figure 4 contained a mistake. The graph of event-free survival in patients with a low International Prognostic Score should indicate that 10 of 18 patients (not 3 of 30) were PET2-positive. The authors regret the error.